Literature DB >> 11893824

Plasma levels of brain natriuretic peptide increase in patients with idiopathic bilateral atrial dilatation.

Mizuhiro Arima1, Tatsuji Kanoh, Yasunobu Kawano, Tetsuya Oigawa, Shinichiro Yamagami, Shigeru Matsuda.   

Abstract

Idiopathic bilateral atrial dilatation (IBAD) is an extremely rare anomaly and is usually associated with atrial fibrillation. Plasma levels of atrial natriuretic peptide (ANP) have been shown to increase in patients with atrial fibrillation. However, secretion of ANP and brain natriuretic peptide (BNP) in patients with IBAD remains unclear. We investigated the clinical features of 9 patients with IBAD and 16 age- and sex-matched patients with lone atrial fibrillation (LAF). Plasma levels of ANP and BNP were measured, and echocardiographic parameters were followed. Left (LAV) and right atrial volumes (RAV) were significantly higher in patients with IBAD than in patients with LAF (both p < 0.01). There were no differences between patients with IBAD and LAF in other echocardiographic parameters. The percent increases in LAV and RAV in patients with IBAD exceeded those in patients with LAF (both p < 0.01). Plasma levels of BNP and the BNP/ANP ratios in patients with IBAD were significantly higher than those in patients with LAF (both p < 0.01), but there was no significant difference in plasma levels of ANP. Regarding the clinical course of the patients with IBAD compared with those with LAF, the atrial volume increased gradually, and plasma levels of BNP were significantly higher. These findings suggested that IBAD was not only influenced by long-term atrial fibrillation, but also by subclinical left ventricular dysfunction. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893824     DOI: 10.1159/000047413

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  5 in total

1.  Plasma brain natriuretic peptide concentrations in patients undergoing pulmonary vein isolation.

Authors:  T Date; T Yamane; K Inada; S Matsuo; S Miyanaga; K Sugimoto; K Shibayama; I Taniguchi; S Mochizuki
Journal:  Heart       Date:  2006-06-01       Impact factor: 5.994

2.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

3.  Brain natriuretic peptide and P wave duration in dialysis patients.

Authors:  M Cagatay Taskapan; Soner Senel; Ozkan Ulutas; Yuksel Aksoy; Ibrahim Sahin; Feridun Kosar; Hulya Taskapan
Journal:  Int Urol Nephrol       Date:  2007-04-25       Impact factor: 2.370

4.  NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure.

Authors:  Isaac R Whitman; Eric Vittinghoff; Christopher R DeFilippi; John S Gottdiener; Alvaro Alonso; Bruce M Psaty; Susan R Heckbert; Ron C Hoogeveen; Dan E Arking; Elizabeth Selvin; Lin Y Chen; Thomas A Dewland; Gregory M Marcus
Journal:  J Am Heart Assoc       Date:  2019-04-02       Impact factor: 5.501

Review 5.  Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation.

Authors:  Masako Baba; Kentaro Yoshida; Masaki Ieda
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.